

Mechanism of actionCombined immunomodulatory drug of bacterial origin. Stimulates both the local cellular and humoral immune response in the mucous membrane of the respiratory tract and the systemic immune response. The drug stimulates the activity of alveolar macrophages, increases the number and activity of T-lymphocytes, activates peripheral monocytes, increases the concentration of secretory IgA on the mucous membranes of the respiratory tract and digestive tract, stimulates the production of protective adhesive molecules, reduces the concentration of IgE antibodies in the blood, also increases the production of cytokines. After taking the drug inside the antigen is captured by the APC cells of the mucous membrane of the gastrointestinal tract. Antigen-stimulated APC cells enter lymphoid organs (for example, Peyer's patches), where they “present” the antigen to lymphoblasts. Then, antigen-stimulated and IgA-committed lymphoblasts migrate with lymph flow through the thoracic duct into the blood and with the blood flow into the mucous membranes (including the respiratory tract), where they are converted into plasma cells and synthesize IgA. Further, IgA is transported to the surface of the mucous membranes in the form of a double molecule, preventing the effects of infectious agents. Indications and usageFor prophylaxis and as part of combination therapy of infectious and inflammatory diseases of the respiratory tract: For prevention of infectious diseases of the respiratory tract appoint 1 caps. / day for 10 days a month for 3 months. Each month, the drug should be taken whenever possible on the same days as the previous one. Adverse reactionsGastrointestinal: rarely - epigastric pain, nausea, vomiting, diarrhea. Contraindications- Hypersensitivity to the drug. Pregnancy and breastfeedingAdequate and strictly controlled clinical studies of the safety of the use of the drug Broncho-Munal during pregnancy and lactation (breastfeeding) were not conducted. Special notesBetween the use of oral vaccines and taking Broncho-Munala should observe a 4-week interval. OverdosageCurrently, cases of overdose of the drug Broncho-Munal were reported. Drug InteractionsDrug interaction of the drug Broncho-Munal is not described. Storage conditionsThe drug should be stored out of the reach of children at a temperature not higher than 25 ° C. Shelf life - 5 years. |